000144615 001__ 144615
000144615 005__ 20240229112631.0
000144615 0247_ $$2doi$$a10.1371/journal.pone.0221350
000144615 0247_ $$2pmid$$apmid:31450235
000144615 0247_ $$2altmetric$$aaltmetric:65736345
000144615 037__ $$aDKFZ-2019-02057
000144615 041__ $$aeng
000144615 082__ $$a610
000144615 1001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b0$$eFirst author$$udkfz
000144615 245__ $$aPrediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
000144615 260__ $$aSan Francisco, California, US$$bPLOS$$c2019
000144615 3367_ $$2DRIVER$$aarticle
000144615 3367_ $$2DataCite$$aOutput Types/Journal article
000144615 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1566905845_19224
000144615 3367_ $$2BibTeX$$aARTICLE
000144615 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144615 3367_ $$00$$2EndNote$$aJournal Article
000144615 520__ $$aRisk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men.The original RM was based on data of 670 biopsy-naïve men from Heidelberg University Hospital who underwent mpMRI with PI-RADS scoring prior to MRI/TRUS-fusion biopsy 2012-2015. Validity was tested by a consecutive cohort of biopsy-naïve men from Heidelberg (n = 160) and externally by a cohort of 133 men from University College London Hospital (UCLH). Assessment of validity was performed at fusion-biopsy by calibration plots, receiver operating characteristics curve and decision curve analyses. The RM`s performance was compared to ERSPC-RC3, ERSPC-RC3+PI-RADSv1.0 and PI-RADSv1.0 alone.SPC was detected in 76 men (48%) at Heidelberg and 38 men (29%) at UCLH. The areas under the curve (AUC) were 0.86 for the RM in both cohorts. For ERSPC-RC3+PI-RADSv1.0 the AUC was 0.84 in Heidelberg and 0.82 at UCLH, for ERSPC-RC3 0.76 at Heidelberg and 0.77 at UCLH and for PI-RADSv1.0 0.79 in Heidelberg and 0.82 at UCLH. Calibration curves suggest that prevalence of sPC needs to be adjusted to local circumstances, as the RM overestimated the risk of harboring sPC in the UCLH cohort. After prevalence-adjustment with respect to the prevalence underlying ERSPC-RC3 to ensure a generalizable comparison, not only between the Heidelberg and die UCLH subgroup, the RM`s Net benefit was superior over the ERSPC`s and the mpMRI`s for threshold probabilities above 0.1 in both cohorts.The RM discriminated well between men with and without sPC at initial MRI-targeted biopsy but overestimated the sPC-risk at UCLH. Taking prevalence into account, the model demonstrated benefit compared with clinical risk calculators and PI-RADSv1.0 in making the decision to biopsy men at suspicion of PC. However, prevalence differences must be taken into account when using or validating the presented risk model.
000144615 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000144615 588__ $$aDataset connected to CrossRef, PubMed,
000144615 7001_ $$aGiganti, Francesco$$b1
000144615 7001_ $$0P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aWiesenfarth, Manuel$$b2$$udkfz
000144615 7001_ $$aStabile, Armando$$b3
000144615 7001_ $$aMarenco, Jose$$b4
000144615 7001_ $$aOrczyk, Clement$$b5
000144615 7001_ $$aKasivisvanathan, Veeru$$b6
000144615 7001_ $$aNyarangi-Dix, Joanne Nyaboe$$b7
000144615 7001_ $$aSchütz, Viktoria$$b8
000144615 7001_ $$0P:(DE-HGF)0$$aDieffenbacher, Svenja$$b9
000144615 7001_ $$aGörtz, Magdalena$$b10
000144615 7001_ $$aStenzinger, Albrecht$$b11
000144615 7001_ $$aRoth, Wilfried$$b12
000144615 7001_ $$aFreeman, Alex$$b13
000144615 7001_ $$aPunwani, Shonit$$b14
000144615 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b15$$udkfz
000144615 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b16$$udkfz
000144615 7001_ $$aHohenfellner, Markus$$b17
000144615 7001_ $$aEmberton, Mark$$b18
000144615 7001_ $$aMoore, Caroline M$$b19
000144615 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0221350$$gVol. 14, no. 8, p. e0221350 -$$n8$$pe0221350 -$$tPLOS ONE$$v14$$x1932-6203$$y2019
000144615 909CO $$ooai:inrepo02.dkfz.de:144615$$pVDB
000144615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000144615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000144615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000144615 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000144615 9141_ $$y2019
000144615 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2017
000144615 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144615 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144615 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144615 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144615 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144615 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144615 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000144615 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000144615 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144615 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144615 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144615 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144615 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144615 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000144615 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144615 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144615 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000144615 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000144615 980__ $$ajournal
000144615 980__ $$aVDB
000144615 980__ $$aI:(DE-He78)E010-20160331
000144615 980__ $$aI:(DE-He78)C060-20160331
000144615 980__ $$aUNRESTRICTED